Mereo BioPharma Group plc

BST:MAH0 Stock Report

Market Cap: €549.0m

Mereo BioPharma Group Management

Management criteria checks 3/4

Mereo BioPharma Group's CEO is Denise Scots-Knight, appointed in Jul 2015, has a tenure of 9.33 years. total yearly compensation is $2.22M, comprised of 25.5% salary and 74.5% bonuses, including company stock and options. directly owns 1.9% of the company’s shares, worth €10.43M. The average tenure of the management team and the board of directors is 6.7 years and 3.6 years respectively.

Key information

Denise Scots-Knight

Chief executive officer

US$2.2m

Total compensation

CEO salary percentage25.5%
CEO tenure9.3yrs
CEO ownership1.9%
Management average tenure6.7yrs
Board average tenure3.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Denise Scots-Knight's remuneration changed compared to Mereo BioPharma Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$45m

Jun 30 2024n/an/a

-US$37m

Mar 31 2024n/an/a

-US$26m

Dec 31 2023US$2mUS$565k

-US$29m

Sep 30 2023n/an/a

-US$31m

Jun 30 2023n/an/a

-US$32m

Mar 31 2023n/an/a

-US$42m

Dec 31 2022US$2mUS$507k

-US$42m

Sep 30 2022n/an/a

-US$31m

Jun 30 2022n/an/a

-US$23m

Mar 31 2022n/an/a

-US$4m

Dec 31 2021US$2mUS$539k

US$17m

Sep 30 2021n/an/a

-US$10m

Jun 30 2021n/an/a

-US$37m

Mar 31 2021n/an/a

-US$131m

Dec 31 2020US$1mUS$545k

-US$224m

Sep 30 2020n/an/a

-US$198m

Jun 30 2020n/an/a

-US$177m

Mar 31 2020n/an/a

-US$111m

Dec 31 2019US$2mUS$518k

-US$46m

Sep 30 2019n/an/a

-US$41m

Jun 30 2019n/an/a

-US$40m

Mar 31 2019n/an/a

-US$41m

Dec 31 2018US$957kUS$484k

-US$41m

Sep 30 2018n/an/a

-US$42m

Jun 30 2018n/an/a

-US$44m

Mar 31 2018n/an/a

-US$50m

Dec 31 2017US$907kUS$493k

-US$52m

Compensation vs Market: Denise's total compensation ($USD2.22M) is above average for companies of similar size in the German market ($USD1.03M).

Compensation vs Earnings: Denise's compensation has been consistent with company performance over the past year.

CEO

Denise Scots-Knight (65 yo)

9.3yrs

Tenure

US$2,219,323

Compensation

Dr. Denise Vera Scots-Knight, Ph.D. serves as President of OncoMed Pharmaceuticals, Inc. She serves as Director at Elanco Animal Health Incorporated since March 13, 2019. She co-founded Mereo BioPharma Gro...

Leadership Team

NamePositionTenureCompensationOwnership
Denise Scots-Knight
Co-Founder9.3yrsUS$2.22m1.9%
€ 10.4m
Charles Sermon
Co-Founder9.5yrsUS$1.09m0.58%
€ 3.2m
Christine Fox
Chief Financial Officer3.8yrsUS$1.00m0.27%
€ 1.5m
John Richard
Co-Founder & Chief Business Officer9.8yrsno datano data
John Lewicki
Chief Scientific Officer4.3yrsno data0.060%
€ 329.0k
Jackie Parkin
Senior VP & Therapeutic Headno datano datano data
Alexandra Hughes-Wilson
Chief of Patient Access & Commercial Planning6.7yrsno data0.033%
€ 178.9k
Suba Krishnan
Senior Vice President of Clinical Development3.9yrsno datano data
Bo Kara
Senior VP and Head of Pharmaceutical Development & CMCno datano datano data

6.7yrs

Average Tenure

62yo

Average Age

Experienced Management: MAH0's management team is seasoned and experienced (6.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Denise Scots-Knight
Co-Founder9.7yrsUS$2.22m1.9%
€ 10.4m
Michael Wyzga
Independent Non-Executive Chairman of The Board5.6yrsUS$156.80k0.016%
€ 88.8k
Deepika Pakianathan
Independent Non-Executive Director5.6yrsUS$113.76k0%
€ 0
Anders Ekblom
Independent Non-Executive Director9.3yrsUS$121.31k0.17%
€ 907.2k
Marc Yoskowitz
Independent Director2yrsUS$94.49k0.049%
€ 267.3k
Annalisa Lisa Jenkins
Independent Director2yrsUS$100.96k0.049%
€ 267.3k
Jeremy Bender
Independent Non Executive Director4.1yrsUS$105.08k0.0081%
€ 44.5k
Daniel Shames
Independent Director2yrsUS$97.75k0.049%
€ 267.3k
Pierre Jacquet
Independent Director3.2yrsUS$102.18k0.10%
€ 548.1k
Justin Roberts
Independent Director2yrsno datano data

3.6yrs

Average Tenure

59yo

Average Age

Experienced Board: MAH0's board of directors are considered experienced (3.6 years average tenure).